Peer-reviewed research from multiple university and medical research centers has investigated whether beta-glucan — the immune-active compound found in the cell walls of yeast and certain mushrooms — can work alongside the immune system to help it recognize and respond to cancer cells. The science centers on a receptor called CR3, found on white blood cells including neutrophils and natural killer cells. In normal circumstances, CR3 does not attack tumor cells effectively, even when those tumors are already tagged with immune markers. Beta-glucan appears to act as a key that 'primes' CR3 — switching it into an active mode that enables it to kill tagged tumor cells.
Laboratory and animal studies by researchers at the University of Louisville and other institutions found that when yeast beta-glucan is taken orally, it is absorbed by immune cells in the gut and eventually makes its way into the bone marrow. There, it transfers to a type of white blood cell called a neutrophil. These primed neutrophils then travel to areas where tumors are marked with immune tags, and they destroy those marked cells. Experiments confirmed this by showing that depleting neutrophils or blocking key signaling molecules eliminated the anti-tumor effect entirely — it was specifically the primed neutrophils doing the work.
Researchers also tested whether combining beta-glucan with anti-cancer antibody drugs (monoclonal antibodies like Herceptin or Rituxan, which are already used in cancer treatment) could be more effective than either alone. Across five different tumor models, the combination consistently outperformed either treatment individually — producing tumor regression in mammary, liver, and other tumors. The researchers proposed that beta-glucan could act as a biological amplifier for these existing antibody therapies by adding a second killing mechanism (neutrophil attack) on top of what the antibodies already do.
A clinical study in 28 patients with digestive cancers found that a related mushroom beta-glucan (lentinan, from shiitake) was able to shift the immune balance in cancer patients from a suppressive pattern toward a more active, anti-tumor pattern. Patients with the most immune suppression showed the greatest shifts. This is important because advanced cancer is often associated with an immune state that actively discourages the body's own defenses from attacking tumor cells. Beta-glucan's ability to rebalance this in human patients — not just in mice — is clinically relevant.
Finally, research by Vetvicka and colleagues published in a peer-reviewed nutraceutical science journal found that oral yeast beta-1,3-glucan not only reduced mortality from anthrax infection in mice, but also inhibited metastatic cancer cell growth in the same experimental conditions. Both effects appeared to operate through the same immune pathways — specifically by boosting IL-2, IFN-gamma, and TNF-alpha. This dual finding in one study underscores that the immune pathways activated by beta-glucan are broad, robust, and relevant to serious infectious and neoplastic threats.
